Betting for the next best thing in digital #diabetes technology:
'#AID systems & algorithms are very effective.
Unfortunately, they are used by a minority of ppl who cld benefit from them.'
-Steven Russell
#EASD2022#dedoc°voices #nothingaboutuswithoutus@#dedoc° 1/n
Betting for the next best thing in digital #diabetes technology:
'In addition to the challenges of getting hybrid #AID systems, they still require setups. They still require the user to #carbcount for meals & initiate correction boluses.'
-Steven Russell
#EASD2022#dedoc 2/n
Betting for the next best thing in digital #diabetes technology:
'Similar results with #ControlIQ studies whereas the #IletBionicPancreas doesn't require carb counting and insulin parameters.' -Steven Russell
It looks promising
#EASD2022#dedoc°voices #payitforward 5/n
Betting for the next best thing in digital #diabetes technology:
'With faster insulin, we can clamp the #BG within a very narrow range.'
-Steven Russell
Mean BG in #T1D group: 107mg
Range: 96-128mg
#TIR: 98%
No hypo
#EASD2022#dedoc°voices @#dedoc° 7/n
Betting for the next best thing in digital #diabetes technology:
'Glucagon could take us further.
2 hormones are missing in #T1D:
#insulin beta cells
#glucagon alpha cells are there but no longer respond to hypo.'
-Steven Russell
#EASD2022#dedoc°voices @#dedoc° 8/n
Betting for the next best thing in digital #diabetes technology:
'#glucagon is the most important defence against #hypo automatic microdosing of glucagon may prevent severity of hypo as it is absorbed much faster than #insulin.' -Steven Russell
#EASD2022#dedoc@#dedoc° 9/n
Betting for the next best thing in digital #diabetes technology:
7-day #IletBionicPancreas study:
Insulin only 72% #TIR
Bi-hormonal 79% #TIR & less hypo
'We now have a stable #glucagon analog: Zegalogue (Dasiglucagon).'
-Steven Russell
#EASD2022#dedoc° 10/n
Betting for the next best thing in digital #diabetes technology:
'In the future, we may have glucose-responsive #insulin that only acts when the glucose is high and is prevented from acting when low.' -Steven Russell
#EASD2022#dedoc°voices #DOC@EASD@#dedoc° 11/n
Betting for the next best thing in digital #diabetes technology:
'Possible adjunct therapies to #AID:
Pramlintide
GLP-1 agonists
SGLT-2 inhibitors'
-Steven Russell
#EASD2022#dedoc°voices
@EASD@#dedoc° 12/n
Betting for the next best thing in digital #diabetes technology:
Ideal bihormonal #ClosedLoop system:
Automated #glucagon
Smart #insulin
Adjunct drugs
The device has been submitted to the FDA - not yet to Europe
#EASD2022#dedoc°voices @#dedoc° 13/n